Table 1.
Baseline characteristics and treatment of USC and Japanese cohorts
| USC* (n=207) | Japanese (n=350) | |||
|---|---|---|---|---|
| n | % | n | % | |
| Age, years | ||||
| <55 | 74 | 35.8 | 70 | 20.0 |
| 55-64 | 75 | 36.2 | 101 | 28.9 |
| ≥65 | 58 | 28.0 | 179 | 51.1 |
| Sex | ||||
| Female | 96 | 46.4 | 175 | 50.0 |
| Male | 111 | 53.6 | 175 | 50.0 |
| T | ||||
| T1 | 2 | 1.0 | 0 | |
| T2 | 12 | 5.8 | 5 | 1.4 |
| T3 | 164 | 79.2 | 232 | 66.3 |
| T4 | 25 | 12.1 | 113 | 32.3 |
| Tx | 4 | 1.9 | ||
| N | ||||
| Negative | 97 | 46.9 | 0 | |
| N1 | 61 | 29.5 | 229 | 65.4 |
| N2 | 49 | 23.7 | 121 | 34.6 |
| Grade | ||||
| Well | 11 | 5.3 | 75 | 21.4 |
| Moderate | 132 | 63.8 | 236 | 67.4 |
| Poor/undifferentiated | 47 | 22.7 | 24 | 6.9 |
| Missing | 17 | 8.2 | 15 | 4.3 |
| Stage | ||||
| II | 97 | 46.9 | 0 | |
| III | 110 | 53.1 | 229 | 65.4 |
| IIIC | 121 | 34.6 | ||
| N of resected lymph nodes | ||||
| ≤12 | 60 | 29.0 | 47 | 13.5 |
| >12 | 129 | 62.3 | 302 | 86.5 |
| Missing | 18 | 8.7 | 1 | |
| Tumor side | ||||
| Right | 98 | 47.3 | 110 | 31.4 |
| Left | 101 | 48.8 | 238 | 68.0 |
| Left and right | 3 | 1.5 | 2 | 0.6 |
| Missing | 5 | 2.4 | ||
| Adjuvant treatment | ||||
| Fluoropyrimidines | 130 | 62.8 | 206 | 58.9 |
| 5-FU/LV/Oxaliplatin | 58 | 28.0 | 68 | 19.4 |
| 5-FU/LV/Irinotecan | 19 | 9.2 | 0 | |
| None | 76 | 21.7 | ||
| Ethnicity | ||||
| Asian | 28 | 13.5 | 350 | 100.0 |
| African American | 14 | 6.8 | ||
| Caucasian | 110 | 53.1 | ||
| Hispanic | 55 | 26.6 | ||